Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study
Journal
Frontiers in oncology
Journal Volume
13
Date Issued
2023
Author(s)
Abstract
The MET exon 14 skipping (METex14) mutation is an important oncogenic driver in lung cancer. We performed a retrospective analysis of clinical data from lung cancer patients with the METex14 mutation to analyze their survival outcomes and associated prognostic factors.
Subjects
MET exon 14 skipping; adenocarcinoma; immunohistochemistry; overall survival; pulmonary sarcomatoid carcinoma
Publisher
FRONTIERS MEDIA SA
Type
journal article